Replay available

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) Q2 2025 earnings conference call, held 2025-08-05. Replay captured from the company's public earnings webcast.

Tue, August 5, 2025 at 4:30 PMendedReplay
Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Tram Bui

Vice President of Investor Relations and Corporate Communications

Dr. Helen Torley

President and Chief Executive Officer

Nicole Labrosse

Chief Financial Officer

Sean Lehman

Analyst, Morgan Stanley

Jason Butler

Analyst, Citizens JMP

Brendan Smith

Analyst, TD Cowen

Michael DeFior

Analyst, Evercore ISI

Mitchell Kapoor

Analyst, HC Wainwright

Corinne Johnson

Analyst, Goldman Sachs

Replay transcript excerpt

Good afternoon. My name is Kayla and I will be your conference operator today. At this time, I would like to welcome everyone to the Halo-Zyme second quarter 2025 financial and operating results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, again, press the star and one. Please note this event is being recorded. I will now turn the call over to Tram Bui, HaloZyme's Vice President of Investor Relations and Corporate Communications. Please go ahead. Thank you, Operator. Good afternoon and welcome to our second quarter 2025 Financial and Operating Results Conference Call. In addition to the press release issued today after the market closed, you could find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, HaloZone's President and Chief Executive Officer, who will provide an update on our business, and Nicole Labrosse, our Chief Financial Officer, will review our financial results as well as our outlook. We will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risk and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation. I will now turn the call over to Dr. Helen Torley. Good afternoon, everyone, and thank you ...

More from Halozyme Therapeutics, Inc.